Introduction
Multiple myeloma is a haematological malignancy characterized by the clonal expansion of malignant plasma cells within the bone marrow. Myeloma cells are almost completely contained within this specialized microenvironment, where they interact with haematopoietic and osteoblastic cells of the bone marrow. These interactions provide critical support for both the survival and growth of myeloma cells, and the development of myeloma bone disease. 1 Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), first discovered in 1995, was heralded as a selective killer of tumour cells. 2, 3 TRAIL has been shown to induce myeloma cell apoptosis in vitro and to have specific antitumour activity in vivo. [4] [5] [6] It interacts with four distinct membrane-bound receptors, inducing apoptosis by acting through the death receptors (DR) 4 and DR5, which have cytoplasmic death domains. TRAIL also binds to DcR1 and DcR2, decoy receptors that either lack a death domain or have a truncated death domain. 7 Whilst it has been suggested that expression of the decoy receptors may confer TRAIL resistance, a clear correlation between expression of TRAIL receptors and response to TRAIL has not been demonstrated. 5, [8] [9] [10] Recent studies have shown that another member of the TNF receptor superfamily, osteoprotegerin (OPG), which is expressed by osteoblasts and bone marrow stromal cells, can function as a soluble decoy receptor for TRAIL. 11, 12 In support of this, we have previously shown that OPG can protect myeloma cells against TRAIL-induced apoptosis, suggesting that OPG may function as a paracrine survival factor in the bone marrow microenvironment. 13 Thus, whilst TRAIL may be an effective and selective anti-tumour agent, the close association between myeloma cells and cells of the bone marrow microenvironment, which secrete OPG, may inhibit the antimyeloma effects of TRAIL. The aim of the present study was to determine whether cells of the bone marrow microenvironment can protect myeloma cells from apoptosis induced by TRAIL, and whether specific agonists of TRAIL death receptors may represent novel therapeutic agents in myeloma which are not inhibited in the bone marrow microenvironment.
Materials and methods

Cell culture
The human myeloma cell lines NCI H929, U266B1 and RPMI 8226 were obtained from the European Collection of Animal Cell Cultures (ECACC; Salisbury, UK) and MG-63 cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). All cells were cultured as described previously. 13 The human osteoblast-like cell line hPOB-tert was kindly provided by Nestec (Nestec Ltd, Nestlé Research Center Lausanne, Switzerland) and was cultured in aMEM containing 10% foetal calf serum (FCS), 1 mM glutamine, 100 u/ml penicillin and 100 mg/ml streptomycin. Primary human bone marrow cells were isolated from explants of trabecular bone marrow obtained, with informed consent and the approval of the hospital ethics committee, from patients undergoing routine hip replacement surgery, as described previously. 13 Conditioned medium from osteoblastic cells was prepared as described previously. 13 Treatment with TRAIL or TRAIL receptor agonist antibodies TRAIL and anti-DR5 (R&D Systems, Abingdon, UK) were supplied lyophilized and were reconstituted in phosphate-buffered saline (PBS) with 0.1% bovine serum albumin. They were added in solution to the culture medium, at a range of concentrations as specified. Anti-DR4 (Abcam, Cambridge, UK) was supplied as a solution in PBS and immobilized on plastic in order to exert its agonistic effect. The antibody was allowed to bind to plastic -either the tissue culture plate or 1 mm diameter polystyrene beads of the same surface area, at 371C for 2 h, after which unbound antibody was removed by washing before adding the cell suspension. Multiple myeloma cells were cultured in suspension at a density of 5 Â 10 5 cells/well of a 24-well plate and treated with TRAIL for 24 h or a TRAIL receptor agonist antibody for 72 h. In separate studies, myeloma cells were cultured with a TRAIL receptor agonist antibody in the presence and absence of 20 mM Z-VAD-FMK. For cocultures, adherent osteoblastic cells were plated at 1 Â 10 5 cells/ml/well of a 24-well plate and allowed to adhere overnight. The next day the medium was removed and myeloma cells were added at 5 Â 10 5 cells/ml/well. TRAIL, a TRAILreceptor agonist antibody or appropriate control were added and the cultures were maintained for a further 24 or 72 h.
Analysis of receptor expression by RT-PCR
Total RNA was isolated using the RNeasy Mini Protocol (Qiagen, Sussex, UK) following the manufacturer's instructions. Total RNA (1 mg) was used for first-strand complementary deoxyribonucleic acid (cDNA) synthesis using Superscript II reverse transcriptase with Oligo (dT) [12] [13] [14] [15] [16] [17] [18] primer (Invitrogen, Renfrew, UK) following the manufacturer's instructions. cDNA (2 ml) was amplified by polymerase chain reaction (PCR) and PCR product sizes were determined by comparison with a 100 bp DNA ladder (Invitrogen). Further details are given in Supplementary Information.
Analysis of receptor expression by flow cytometry
Cells were washed once in 1 ml wash buffer (PBS containing 1% FCS), resuspended in 100 ml wash buffer and labelled with mouse anti-human DR4, mouse anti-human DR5 (Diaclone, Besancon, France), mouse anti-human DcR1 or mouse antihuman DcR2 (R&D Systems) or an isotype control mouse IgG 1 (Diaclone) or IgG 2B (R&D Systems) for 30 min. All antibodies were directly conjugated to phycoerythrin (PE). Cells were then washed twice in PBS and resuspended in 300 ml PBS for flow cytometric analysis. The level of PE fluorescence was measured using a FACSCalibur flow cytometer (Becton Dickinson).
Identification and measurement of apoptotic cells
Cell number was determined by measurement of Alamar Blue fluorescence, following the manufacturer's instructions (Serotec, UK). Apoptosis was measured using a fluorescence in situ nick translation (NT) assay as described previously.
14 In co-cultures, the cell suspension was double labelled with a PE-conjugated antibody to kappa or lambda light chains (Dako, Ely, Cambridgeshire, UK), as appropriate for the myeloma cell line, added at the same time as the final staining step of the NT assay. This allowed identification of the different cell populations so that the proportion of apoptotic cells in each population could be analysed. Apoptosis was confirmed in separate experiments by visualization of nuclear morphology after 4,6-diamidino-2-phenylindole (DAPI) staining as described previously.
14 Caspase 3 and 7 activity was measured using a commercially available luminescent assay, following the manufacturer's instructions (Promega, Madison, WI, USA). Cleavage of the caspase 3/7 substrate resulted in an increase in luminescence proportional to the amount of caspase activity present.
Statistical analysis
All of the experiments were performed in quadruplicate and repeated on at least two separate occasions unless stated otherwise. Results are expressed as mean7s.e. Comparisons between control and treatment groups were performed using Student's t-test. Comparisons between multiple groups were performed using a one-way analysis of variance. Figure 1a ), but not all of these were expressed on the cell surface when analysed by flow cytometry (Figure 1b) . Specifically, NCI H929 cells expressed DR4 and DR5 at similar levels, but no DcR1 or DcR2, whereas RPMI 8226 cells expressed high levels of DR4, lower levels of DR5 and very low levels of DcR2, but no DcR1. TRAIL caused a timedependent induction of apoptosis in both RPMI 8226 and NCI H929 myeloma cells, inducing a greater than two-fold increase in apoptosis at 50 ng/ml after 24 h (Figure 1c ). To confirm that TRAIL was acting through the known death receptors, we treated myeloma cells with TRAIL in combination with either a soluble antagonist antibody to DR4 or a soluble form of DR5. Both were able to induce a reduction in apoptosis, confirming that both receptors are involved in apoptotic signalling (Figure 1d ). Treatment with TRAIL did not increase or induce expression of TRAIL receptors on the cell surface (data not shown).
TRAIL receptor agonists induce apoptosis of human myeloma cells
We have previously demonstrated that TRAIL can dosedependently increase apoptosis in human myeloma cells, and we investigated in this study whether agonists of TRAIL death receptors could also induce apoptosis of myeloma cells. We used anti-DR5, a polyclonal agonist antibody to TRAIL receptor 2 extracellular domain, and anti-DR4, a monoclonal antibody to TRAIL receptor 1, which acts as an agonist after crosslinking to plastic. Anti-DR5 significantly induced apoptosis ( Figure 2b ) and reduced cell number (Figure 2d ) in NCI H929 and RPMI 8226 myeloma cells, although to a somewhat lesser extent than TRAIL, and the effect also took longer to become evident. However, after 72 h treatment with 1 mg/ml anti-DR5 apoptosis had increased approximately two-fold and cell number was reduced to 40% of control. Similarly, anti-DR4 at 100 mg/ml, immobilized on plastic, increased apoptosis to 1.4-and 1.75-fold, in NCI H929 and RPMI 8226 cells respectively at 72 h (Figure 2a) , and induced a concomitant reduction in cell number (Figure 2c ). 
Myeloma cell death induced by TRAIL receptor agonists is associated with an increase in caspase activity
To investigate the mechanism of apoptosis induction by the agonists of DR4 and DR5 in human myeloma cells, we treated Targeting TRAIL death receptors in multiple myeloma RM Locklin et al RPMI 8226 and NCI H929 myeloma cells with increasing concentrations of anti-DR4 and anti-DR5, using the same concentrations that we had previously demonstrated were sufficient to induce myeloma cell apoptosis. This treatment resulted in a significant dose-dependent increase in caspase 3/7 activity (Po0.05) (Figure 3a-b) . Furthermore, to confirm the involvement of caspases in myeloma cell death induced by agonists of the TRAIL death receptors, we treated myeloma cells with anti-DR4 or anti-DR5 in the presence and absence of 20 mM Z-VAD-FMK, an irreversible pan caspase inhibitor. Z-VAD-FMK was able to decrease apoptosis and significantly prevent the reduction in cell number induced by either anti-DR4 or anti-DR5 in RPMI 8226 myeloma cells (Figure 3c) . Identical results were observed in NCI H929 myeloma cells (data not shown).
Myeloma cell apoptosis induced by agonists of DR4 or DR5 is not prevented by OPG or osteoblast-conditioned medium
TRAIL-induced apoptosis of human myeloma cells is inhibited by OPG or medium conditioned by osteoblasts, 13 however, apoptosis induced by agonists of TRAIL death receptors may not be subject to this inhibition. rhOPG (100 ng/ml) protected myeloma cells from apoptosis induced by TRAIL but had no significant effect on apoptosis induced by anti-DR5 (Figure 4a) . Similarly, apoptosis of NCI H929 cells induced by TRAIL could be prevented by concurrent treatment with 20% conditioned medium from MG-63 cells. In contrast, apoptosis of NCI H929 cells induced by anti-DR5 or of RPMI 8226 cells induced by anti-DR4 was not inhibited by 20% conditioned medium from MG-63 cells or hPOB-tert cells (Figure 4b-d) . Conditioned medium from MG-63 cells was shown by enzyme-linked immunosorbent assay to contain approximately 800 ng/ml OPG, while that from hPOB-tert cells contained approximately 400 pg/ml OPG.
Myeloma cells cultured in the presence of osteoblasts are protected from TRAIL-induced apoptosis, but not from apoptosis induced by anti-DR4 or anti-DR5
Myeloma cells grow preferentially in the bone marrow microenvironment, in close contact with osteoblasts and bone marrow stromal cells. Therefore, we investigated whether direct contact of myeloma cells with osteoblasts could protect them from apoptosis induced by TRAIL or agonists of TRAIL death receptors. No change in TRAIL receptor expression levels could be detected, either by RT-PCR or flow cytometry, following treatment of myeloma cells with rhOPG or 20% MG-63 conditioned medium in any of the cell lines tested (data not shown). Co-culture of NCI H929 cells with MG-63 osteoblastlike cells (Figure 5a ) was able to block apoptosis induced by TRAIL, as measured by a nick translation assay. Similar results were observed in co-cultures using RPMI 8226 cells (data not shown). The same protective effect was observed with normal hPOB-tert osteoblastic cells or with primary human marrow stromal cells, where co-culture with osteoblastic cells reduced TRAIL-induced apoptosis of NCI H929 myeloma cells from over 55% to a baseline value of 15%, and of RPMI 8226 cells from 65% to 20%. To confirm that OPG produced by osteoblastic cells was responsible for the protective effect, the presence of a neutralizing antibody to OPG in myeloma cell/osteoblast cocultures treated with TRAIL completely abolished the protective effect of the osteoblastic cells, increasing TRAIL-induced apoptosis from a modest increase of 40% over untreated controls to an induction of over two-fold in the presence of the neutralizing antibody (Figure 5b ). In contrast, myeloma cell apoptosis induced by anti-DR4 bound to polystyrene beads, or by anti-DR5, was not blocked by co-culture with hPOB-tert cells, MG-63 cells or normal primary human marrow cells (Figure 5c-d) . 
Discussion
Multiple myeloma remains an incurable haematological malignancy, which is further complicated by the protective effects of cells of the local bone marrow microenvironment. Osteoblasts and bone marrow stromal cells are known to support the growth and survival of myeloma cells, and many studies have demonstrated the protective effects of these cells against varying antimyeloma therapies. Whilst TRAIL has potent antimyeloma effects in cell lines in vitro and in a plasmacytoma model in vivo, 4,5 the critical interactions between myeloma cells and cells of the bone marrow microenvironment are not reflected in these studies. In the present study, we demonstrate that bone marrow stromal cells and osteoblastic cells can protect myeloma cells from apoptosis induced by TRAIL. This protective effect is shown to be dependent upon OPG released from the osteoblastic cells, as the effect can be completely prevented by a neutralizing antibody to OPG. These findings are in agreement with those recently described by Tinhofer et al. 15 using a similar co-culture system. In contrast with their findings, however, we found that TRAIL had no effect on apoptosis of normal osteoblastic cells, either alone or in co-culture.
The RANK/RANKL/OPG system plays a key role in the development of myeloma bone disease, and has been proven to be an effective therapeutic target, with a recent study by Body et al. 16 demonstrating the efficacy of a human monoclonal antibody to RANKL in inhibiting bone resorption in patients with multiple myeloma. The RANKL/OPG ratio is dysregulated in Targeting TRAIL death receptors in multiple myeloma RM Locklin et al multiple myeloma, 17 with an increase in RANKL contributing to the development of myeloma bone disease. Increased RANKL expression has been demonstrated both on myeloma cells and on stromal cells, although the primary cellular source of RANKL that contributes to the development of myeloma bone disease in vivo is unclear. [18] [19] [20] [21] [22] OPG is decreased in the serum of patients with multiple myeloma, 23 and this effect is mirrored in vitro by co-cultures of myeloma cells and osteoblasts, where myeloma cells downregulate OPG.
13, 24 However, we have demonstrated that the concentration of OPG remaining is still sufficient to protect myeloma cells from apoptosis induced by TRAIL. 13 Furthermore, although the later stages of multiple myeloma are associated with a decrease in osteoblast number, there are a number of other cell types within the bone marrow microenvironment, including stromal cells, endothelial cells and megakaryocytes, which release OPG and have the potential to protect myeloma cells against TRAIL-induced apoptosis in a similar manner to osteoblasts. Flow cytometric analysis demonstrated expression of DR4 and DR5 on the surface of NCI H929 and RPMI 8226 myeloma cells. The use of an antagonistic antibody to DR4 or a soluble form of DR5 was shown to significantly inhibit TRAIL-induced apoptosis of myeloma cells, confirming that both receptors were functioning to mediate the apoptotic effect of TRAIL. TRAIL receptor expression was not regulated by exposure to TRAIL or by cells of the bone marrow microenvironment. Therefore, we hypothesized that specific agonists of the TRAIL death receptors would not be inhibited in the bone marrow microenvironment and thus may represent a novel therapeutic approach for the treatment of multiple myeloma.
Previous studies have suggested that agonist antibodies to the TRAIL receptors could provide a safer alternative to TRAIL therapy without the hepatocyte cytotoxicity that has been associated with TRAIL. 25, 26 A series of recently developed agonist antibodies are currently undergoing phase I and II clinical trials for use in solid tumours. 27 To date, however, none of these approaches have been tested in myeloma cells in the bone marrow environment. In this study, specific agonistic antibodies to DR4 or DR5 were found to significantly inhibit myeloma cell proliferation and induce myeloma cell apoptosis, effects that were, at least partially, dependent upon an increase in caspase activity. These observations are supported by a recent study by Menoret et al. 28 who demonstrate the involvement of Mcl-1L in apoptosis induced by human mAbs directed against DR4 and DR5. Although NCI H929 and RPMI 8226 myeloma cells had a similar magnitude of response to anti-DR5, RPMI 8226 myeloma cells were more sensitive to anti-DR4. This sensitivity most likely reflects the increased expression of DR4 on the surface of RPMI 8226 cells compared to NCI H929 myeloma cells, as demonstrated by a significant increase in fluorescence. In contrast to TRAIL, apoptosis induced by anti-DR4 or anti-DR5 was not prevented by recombinant OPG or by medium conditioned by osteoblasts or bone marrow stromal cells. More importantly, the antimyeloma effects induced by anti-DR4 or anti-DR5 were not inhibited when myeloma cells were cultured in the presence of osteoblastic cells. Whilst the myeloma cells were very sensitive to apoptosis induced by anti-DR4 or anti-DR5, normal human osteoblasts (hPOB-tert) did not undergo cell death in response to the TRAIL death receptor agonists, demonstrating that, similar to TRAIL, myeloma cells are more sensitive than normal cells in their response to agonists of TRAIL death receptors.
TRAIL has been proposed as a potential anti-tumour therapy, but within the bone marrow microenvironment OPG produced by osteoblastic cells may interfere with its action and thus limit its effectiveness in multiple myeloma. We show that specific agonist antibodies to active apoptosis-inducing TRAIL receptors would not be affected by OPG or cells of the bone marrow microenvironment and thus offer an alternative possibility for specific antimyeloma therapy.
